Aqemia announced it is broadening and accelerating its computational platform to target RNAs using its physics-enabled generative AI engine. Creating on successes in epitranscriptomics, Aqemia looks to develop novel small-molecule drugs against this emerging and promising class of therapeutic targets. And in parallel with advancing RNA-focused initiatives, the company continues to drive innovation in its broader pipeline, including protein-targeting programs.
Aqemia secured a $7.4 million grant for the France 2030 plan. This funding will strengthen the company’s generative AI platform to handle highly flexible proteins and RNA targets. For instance, Aqemia plans to experimentally determine various RNA and RNA-modifying targets to refine and iterate its technology.
RNAs have long been a promising but difficult class of therapeutic targets due to their inherently flexible and complex structures. However, their pivotal role in gene regulation and expression—especially in diseases like cancer—makes them highly strategic for innovative drug discovery efforts.
Aqemia has already advanced several drug discovery programs in RNA targeting, bringing them closer to clinical trials. One such program, in partnership with Novalix, has shown a strong effect on cancer cells and is currently progressing in vivo models.
KEY QUOTES:
“This funding enables us to extend the reach of our technology to previously unexplored targets, opening the door to new classes of treatments. Integrating RNA targeting into our platform reinforces our ambition to transform the invention of new therapeutic solutions for patients. We are grateful for the continued support that allows us to push boundaries and tackle critical medical challenges.”
- Dr. Maximilien Levesque, CEO and Co-Founder of Aqemia
